Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

19

Revenue 2017

Keytruda

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Keytruda was produced by Merck & Co..

Keytruda improves survival in first-line oesophageal cancer

Keytruda improves survival in first-line oesophageal cancer The phase 3 KEYNOTE-590 trial evaluated Keytruda (pembrolizumab) in combination with chemotherapy in first-line oesophageal cancer. ... Currently, Bristol Myers Squibb’s rival checkpoint inhibitor Opdivo (nivolumab) is Keytruda’s only potential

AZ scores FDA priority review for new Imfinzi fixed-dose regimen

AZ scores FDA priority review for new Imfinzi fixed-dose regimen Merck &Co’s checkpoint inhibitor Keytruda (pembrolizumab) currently holds much of the NSCLC market, although the drug failed to show benefit in SCLC when added to chemotherapy.

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC

Eli Lilly, Innovent showcase Tyvyt data in first-line NSCLC Tyvyt’s major rival is Merck &Co’s Keytruda (pembrolizumab), which holds approvals across a range of NSCLC indications. ... Keytruda has quickly been established as the new standard of care in NSCLC, after data from the KEYNOTE-189 study found that

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq combo fails in advanced triple negative breast cancer TNBC is an important niche for Roche’s checkpoint inhibitor, in a class that is otherwise dominated by Merck &Co’s PD-1 inhibitor Keytruda (pembrolizumab). ... Despite the fail in TNBC, Keytruda is far ahead of its rivals in terms of revenues,

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer

Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer decline. Despite the NSCLC market being largely dominated by Merck &Co’s Keytruda (pembrolizumab), the ALK-positive patient group is an important subset, with this type of tumour mutation occurring in

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...
The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....